Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CI9T
|
|||
| Former ID |
DCL000744
|
|||
| Drug Name |
Ceftobiprole
|
|||
| Synonyms |
BAL 9141; BAL 9141-000; BAL-9141; Ro 63-9141; Ro-63-9141; Ro-63-9141/000; (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Community-acquired pneumonia [ICD-11: CA40.Z] | Phase 3 | [1] | |
| Skin and skin-structure infection [ICD-11: 1F28-1G0Z] | Phase 3 | [2] | ||
| Company |
Johnson & Johnson
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N8O6S2
|
|||
| Canonical SMILES |
C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O
|
|||
| InChI |
1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
|
|||
| InChIKey |
VOAZJEPQLGBXGO-SDAWRPRTSA-N
|
|||
| CAS Number |
CAS 209467-52-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:140407
|
|||
| ADReCS Drug ID | BADD_D00404 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroides was decreased by Ceftobiprole. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was not significantly changed by Ceftobiprole. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacter
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterobacter was not significantly changed by Ceftobiprole. | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was decreased by Ceftobiprole. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium was increased by Ceftobiprole. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was decreased by Ceftobiprole. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillus was not significantly changed by Ceftobiprole. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03439124) Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03137173) Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections. U.S. National Institutes of Health. | |||
| REF 3 | Effect of ceftobiprole on the normal human intestinal microflora. Int J Antimicrob Agents. 2010 Dec;36(6):537-41. | |||
| REF 4 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.